PharmExec Picks:
Having trouble viewing this e-mail? Click here.
feed back

Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE


Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media.


Top 5 Stories :
Why the Emotional Sell is More Critical Than Ever
The role that emotion plays in the sales process is often underestimated. Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.

Read more

Too Many Breakthroughs?
The FDA program to expedite the development and approval of innovative drugs for serious and life-threatening conditions is a great success, but determining whether an experimental compound has real transformative potential is proving to be a challenge for sponsors and for the agency.
Read more

Four Launch Mistakes and How to Avoid Them
Anyone who has spent any significant time in pharmaceutical marketing has experienced the sheer terror of a brand launch. Years of research and planning culminate in a single moment; personal and corporate reputations and vast sums of money are at stake.
Read more

Towards Real-World Patient Centricity
Have you ever given up on a jar of preserves because you couldn’t get the lid off? Imagine if that was your medication for rheumatoid arthritis (RA), prescribed to you so you could better use your hands.
Read more

Australia Recommends Automatic Substitution of Biosimilars at Pharmacy Level
Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that biosimilars are suitable for substitution at the pharmacy level.
Read more

Trending on Social Media :
Can Facebook Hurt Your Clinical Trial?
That intriguing question raises important issues about how widespread patient sharing of information over the Internet can both support and undermine efforts to obtain meaningful results from biopharmaceutical research studies.
Read more

Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug Adherence
Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority.
Read more

Bristol-Myers Squibb "Will Win Big with Melanoma Combination Immunotherapy"
Following by Bristol-Myers Squibb’s (BMS) presentation of data relating to Opdivo/Yervoy at this year's ASCO meeting, GlobalData has stated that, once approved, this combination of immunotherapies to treat metastatic melanoma "will shape the therapeutic landscape".
Read more

Follow Us